Oral diuretics: Combined therapy with Spironolactone and Furosemide (ratio of 100 mg to 40 mg to maintain potassium balance). c
Spironolactone (Aldosterone Antagonist):
Primary agent: Addresses the root cause of sodium retention by directly blocking mineralocorticoid receptors in the distal tubule/collecting duct.
Prevents Na+ reabsorption and potassium (K+) excretion.
Limitation: Weak diuretic on its own; slow onset of action (takes 2-4 days to reach full effect).
Furosemide (Loop Diuretic):
Inhibits Na+−K+−2Cl− cotransporters in the thick ascending limb of the loop of Henle.
Potent and fast-acting: Rapidly increases urinary flow and sodium excretion.
Limitation: If used alone, the excess Na+ delivered downstream to the distal tubule is simply reabsorbed due to the hyperaldosteronism state.
Second-line:
Large-Volume Paracentesis (LVP) for refractory ascites or tense ascites causing respiratory compromise.
Administer IV Albumin (6-8 g per Liter of fluid removed) if > 5 L of fluid is extracted to prevent post-paracentesis circulatory dysfunction.
Refractory / Definitive:
Transjugular Intrahepatic Portosystemic Shunt (TIPS) (relieves portal HTN; contraindicated in severe hepatic encephalopathy or HF).
Liver transplantation.
Non-Portal HTN ascites (SAAG < 1.1):
Diuretics are generally ineffective; must treat the underlying etiology directly (e.g., chemotherapy for malignancy, anti-TB therapy, steroid therapy for nephrotic syndrome).